369
Views
20
CrossRef citations to date
0
Altmetric
CLINICAL STUDY

The Role of Prolidase Activity in the Diagnosis of Uremic Bone Disease

, M.D., , M.D., , M.D., , M.D. & , M.D.
Pages 271-274 | Published online: 07 Jul 2009

REFERENCES

  • Akoglu E, Suleymanlar G. Chronic renal failure. Internal Medicine, G Ilicin, K Biberoglu, G Suleymanlar, S Unal. Gunes Publication, Ankara 2003; 1298–1308
  • Iyidogan YO, Gurdol F, Oner P. Assessment of serum prolidase activity as bone production-destruction index. J. Istanbul Medical School 1999; 62: 2–7
  • Arata J, Umemura S, Yamamoto Y, Hagiyama M, Nohara N. Prolidase deficiency: its dermatological manifestations and some additional biochemical studies. Arch. Dermatol 1979; 115: 62–67, [INFOTRIEVE], [CSA], [CROSSREF]
  • Hui KS, Lajtha A. Prolidase activity in brain: comparison with other organs. J. Neurochem 1978; 30: 321–327, [INFOTRIEVE], [CSA]
  • Zuyderhoudt FM, Brugman AM, Smit JJ, de Jong L. Plasma prolidase in the rat: no index of liver fibrosis. Clin. Chem 1985; 31: 662, [INFOTRIEVE], [CSA]
  • Myara I. Effect of long preincubation on the two forms of human erythrocyte prolidase. Clin. Chim. Acta 1987; 170: 263–270, [INFOTRIEVE], [CSA], [CROSSREF]
  • Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999; 55: 2141–2156, [INFOTRIEVE], [CSA], [CROSSREF]
  • Urena P, Hruby M, Ferreira A, Ang K, de Vernejoul M. Plasma total versus bone alkaline phosphatase as marker of bone turnover in hemodialysis patients. J. Am. Soc. Nephrol 1996; 7: 506–512, [INFOTRIEVE], [CSA]
  • Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella D, Mazzaferro S, Napoletano I, Sardella D, Taggi F. Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients. Nephrol. Dial. Transplant 1998; 13: 2294–2302, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Urena P, Ferreira A, Kung V, Morieu C, Simon P, Ang K, Souberbielle J, Segre G, Drüeke T, de Vernejoul M. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J. Bone Miner. Res 1995; 10: 932–939, [INFOTRIEVE], [CSA]
  • Naik RB, Gosling P, Price CP. Comparative study of alkaline phosphatase isoenzymes, bone histology and skeletal radiography in dialysis bone disease. Br. Med. J 1977; 1: 1307–1310, [INFOTRIEVE], [CSA]
  • Lau K, Orishi T, Wergedal J, Singer F, Baylink D. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin. Chem 1987; 33: 458–462, [INFOTRIEVE], [CSA]
  • Couttenye MM, D'Haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of European CAPD population. Nephrol. Dial. Transplant 1997; 12: 2144–2150, [INFOTRIEVE], [CSA], [CROSSREF]
  • Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. J. Biol. Chem 1994; 269: 14853–14856, [INFOTRIEVE], [CSA]
  • Lopez Gavilanes E, Gonzalez Parra E, de la Piedra C, Caramelo C, Rapado A. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. Miner. Electrolyte Metab 1994; 20: 259–264, [INFOTRIEVE], [CSA]
  • Stepan JJ, Silinkova-Malkova E, Havranek T, Formankova J, Zichova M, Lachmanova J, Strakova M, Broulik P, Pacovsky V. Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin. Chim. Acta 1983; 133(30)189–200, [INFOTRIEVE], [CSA]
  • Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J. Clin. Endocrinol. Metab 1992; 75: 145–150, [INFOTRIEVE], [CSA], [CROSSREF]
  • Sherrard DJ, Baylink DJ, Wergedal JE, Maloney NA. Quantitative histological studies on the pathogenesis of uremic bone disease. J. Clin. Endocrinol. Metab 1974; 39: 119–135, [INFOTRIEVE], [CSA]
  • Erbagci AB, Araz M, Erbagci A, Tarakcioglu M, Namiduru ES. Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin. Biochem 2002; 35: 263–268, Erratum in: Clin. Biochem. 2003;36(8):667[INFOTRIEVE], [CSA], [CROSSREF]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.